profit from every ZAR 100 of sales.
ZAR 0ZAR 100
Aspen Pharmacare Holdings
ZAR 176.50-1.16% today
+86.9% in 1 year
1-year low ZAR 93.981-year high ZAR 178.58
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Aspen Pharmacare Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from ZAR 100 of sales | Sales growth a year | Price per ZAR 1 of profit |
|---|---|---|---|
| Aspen Pharmacare Holdings | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Aspen Pharmacare Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 0.8×
- 1.8×
- 734.7×
- –
- 0.1%
- -1.4%
- –
Profitability
- 44.1%
- 19.9%
- -2.5%
- –
- 0.9%
- 4.4%
- –
- –
- –
- –
Growth
- +3.9%
- –
- –
- –
- −0.7%
Financial health
- 8.2×
- 0.43
- –
- 0.9×
- 2.21
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 32%of 964
Top 27%of 898
Bottom 26%of 911
Bottom 37%of 991
News
Aspen GAAP EPS of -$0.14, revenue of $10.3MSeeking Alpha · Aug 18, 2026The newest story we have is from Aug 18, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
61Pass
Philip Fisher
31No pass
Peter Lynch
34No pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
21No pass
Questions about Aspen Pharmacare Holdings
Is Aspen Pharmacare Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aspen Pharmacare Holdings AI analysis
What does Aspen Pharmacare Holdings do?
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It is in Drug Manufacturers - Specialty & Generic.
Is Aspen Pharmacare Holdings stock halal?
No. Aspen Pharmacare Holdings does not pass our halal screen: its debt is 47% of its market value, at or above the 33% limit. How we check
How has Aspen Pharmacare Holdings stock done over the past year?
Up 86.9% over the past twelve months, to ZAR 176.50. It traded between ZAR 93.98 and ZAR 178.58, close to its high.
Who are Aspen Pharmacare Holdings's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Aspen Pharmacare Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.